Several preclinical infectious-disease and drug-delivery advances stood out for their mechanistic specificity. A niosome-encapsulated formulation of cefoxitin halved MICs against Gram-positive bacteria and enabled activity against Gram-negative strains and biofilms that the free drug could not address in vitro. Separately, engineered phage protein lysed Streptococcus suis biofilms by combining cell-wall lysis and capsule degradation, demonstrating both prevention and clearance in vitro and in a mouse model. Together, the reports reflect a push toward delivery systems and biologics that tackle biofilm-protected bacterial states—often a key driver of treatment failure. While none of these updates indicate immediate regulatory milestones, they are representative of the innovation pipeline shifting toward combination mechanisms that can penetrate or dismantle biofilm defenses.